期刊文献+

抗血小板药物研究进展 被引量:2

Research Progress in Antiplatelet Agents
下载PDF
导出
摘要 自20世纪90年代以来,随着我国人口老龄化程度日益加剧,并受生活节奏加快、饮食结构不合理等因素影响,心脑血管疾病发病率处于上升趋势,对居民健康造成严重威胁。抗血小板药物作用于血小板激活、粘附、聚集的各个环节,在治疗心血管疾病、预防血栓事件、降低心脑血管疾病死亡率等方面起着显著的作用。本文对抗血小板药物的分类、作用机制、临床应用进展等进行综述。 With aging , quickening pace of life and poor diet the morbidity of cardiovascular and cerebrovascular diseases is rising which are harmful for the health of the people .Antiplatelet agents affect on every link of platelet activation , adhesion and aggregation . They play an important role in the treatment of these diseases , prevention of thromboembolic events and reductionof the mortality of these disease.This article reviews the classification , mechanism and progress in clinical application of these agents .
作者 王辰 曹蘅
出处 《国际老年医学杂志》 2014年第4期183-186,共4页 International Journal of Geriatrics
关键词 抗血小板药物 阿司匹林 氯吡格雷 普拉格雷 替罗非班 Antiplatelet agents Aspirin Clopidogrel Prasugrel Tirofiban
  • 相关文献

参考文献24

  • 1Osende JI, Shimbo D, Fuster V, et al. Antithrombot- ic effects of S18886, a novel orally active throm boxane A2 receptor antagonist [ J ]. J Thromb Haemost, 2004, 2 (3): 492-498. 被引量:1
  • 2Mearns BM. Antiplatelet therapy: terutroban does not out- PERFORM aspirin in secondary prevention [ J ]. Nature reviews Cardiology, 2011, 8 (8) : 423. 被引量:1
  • 3Barrett NE, Holbrook L, Jones S, et al. Future inno- vations in antiplatelet therapies [ J ]. Br J Pharmacol, 2008, 154 (5): 918-939. 被引量:1
  • 4韩红路.新型抗血小板聚集剂西洛他唑[J].中国科技信息,2005(9):55-55. 被引量:16
  • 5Lepantalo A, Virtanen KS, Resendiz JC, et al. Anti- platelet effect of clopidogrel in patients with aspirin ther- apy undergoing percutaneous coronary interventions - limited inhibition of the P2Y12 receptor [J]. Thromb Res, 2009, 124 (2) : 193 -198. 被引量:1
  • 6Small DS, Farid NA, Li YG, et al. Effect of raniti- dine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel [ J ]. Curr Med Res Opin,2008, 24 (8): 2251-2257. 被引量:1
  • 7Fraid NA, Small DS, Payne CD, et al. Effect of ator- vastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects [ J ]. Pharmacotherapy, 2008, 28 (12): 1483-1494. 被引量:1
  • 8吴雅凝,赵娣,李宁,陈西敬.二磷酸腺苷受体拮抗剂类抗血小板药物研究进展[J].中国临床药理学与治疗学,2010,15(12):1434-1440. 被引量:9
  • 9Hashemzadeh M, Goldsberry S, Furukawa M, et al. ADP receptor - blocker thieno - pyridines : Chemical structrues, mode of action and clinical use a review [J]. J Invasive Cardiol, 2009, 21 (8) : 406 -412. 被引量:1
  • 10Jernberg T, Payne CK, Winters K J, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non - responders compared with clopi- dogrel in asprin treated patients with stable coronary art ery disease [ J]. Eur Heart J, 2006, 27 (10): 1166 - 1173. 被引量:1

二级参考文献52

  • 1周中和,王景周,曲方,何祥,陈曼娥,王耀山.局部应用重组水蛭素对脑出血模型大鼠血肿周边组织损伤的干预作用[J].中风与神经疾病杂志,2004,21(3):202-204. 被引量:17
  • 2陈洪,郭伟,陈建良,杨地,吴耀晨,邓佳鸿.术中应用水蛭素治疗出血后脑水肿[J].中国临床神经外科杂志,2006,11(7):406-407. 被引量:9
  • 3李开龙,何娅妮,张建国,杨聚荣,丁涵露,王惠民.水蛭素治疗特发性膜性肾病的回顾性分析[J].中国中西医结合肾病杂志,2007,8(7):417-418. 被引量:29
  • 4郑宏,翟文生,任现志,汪受传.黄芪、水蛭含药血清对大鼠肾小球系膜细胞产生TGF-β1的影响[J].天津医药,2007,35(7):509-511. 被引量:10
  • 5Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ, 2002, 324(7329): 71-86. 被引量:1
  • 6Bertrand ME, Rupprecht H J, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study[J]. Circulation, 2000, 102(6), 624--629. 被引量:1
  • 7Gur S, Kadowitz PJ, Hellstrom WJ. Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview[J]. Curr PharmDes, 2007, 13(31): 3236-3244. 被引量:1
  • 8Knudsen JB, Bastain W, Sefton CM, et al. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics [J]. Xenobiotica, 1992, 22(5): 579--589. 被引量:1
  • 9Ha-Duong NT, Dijols S, Macherey AC, et al. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19 [J]. Biochemistry,2001, 40(40): 12112-12122. 被引量:1
  • 10Caplain H, Donat F, Gaud C, et al. Pharmacokinetics of clopidogrel [J]. Semin Thromb Hemost, 1999, 25(Suppl 2): 25-28. 被引量:1

共引文献67

同被引文献9

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部